- Home
- DOMH vs QNCX Comparison
DOMH vs QNCX Comparison
Compare DOMH & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOMH
- QNCX
- Stock Information
- Founded
- DOMH 1967
- QNCX 2012
- Country
- DOMH United States
- QNCX United States
- Employees
- DOMH N/A
- QNCX N/A
- Industry
- DOMH Biotechnology: Pharmaceutical Preparations
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DOMH Health Care
- QNCX Health Care
- Exchange
- DOMH Nasdaq
- QNCX Nasdaq
- Market Cap
- DOMH 94.0M
- QNCX 85.9M
- IPO Year
- DOMH N/A
- QNCX 2019
- Fundamental
- Price
- DOMH $6.47
- QNCX $1.90
- Analyst Decision
- DOMH
- QNCX Strong Buy
- Analyst Count
- DOMH 0
- QNCX 6
- Target Price
- DOMH N/A
- QNCX $8.00
- AVG Volume (30 Days)
- DOMH 366.7K
- QNCX 371.2K
- Earning Date
- DOMH 11-07-2025
- QNCX 11-12-2025
- Dividend Yield
- DOMH 8.35%
- QNCX N/A
- EPS Growth
- DOMH N/A
- QNCX N/A
- EPS
- DOMH N/A
- QNCX N/A
- Revenue
- DOMH $52,811,000.00
- QNCX N/A
- Revenue This Year
- DOMH N/A
- QNCX N/A
- Revenue Next Year
- DOMH N/A
- QNCX N/A
- P/E Ratio
- DOMH N/A
- QNCX N/A
- Revenue Growth
- DOMH 455.38
- QNCX N/A
- 52 Week Low
- DOMH $0.83
- QNCX $0.69
- 52 Week High
- DOMH $13.58
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- DOMH 49.43
- QNCX 59.30
- Support Level
- DOMH $6.53
- QNCX $1.64
- Resistance Level
- DOMH $7.54
- QNCX $2.05
- Average True Range (ATR)
- DOMH 0.61
- QNCX 0.10
- MACD
- DOMH -0.05
- QNCX 0.02
- Stochastic Oscillator
- DOMH 14.75
- QNCX 43.75
About DOMH Dominari Holdings Inc.
Dominari Holdings Inc through its various subsidiaries, is currently engaged in wealth management, investment banking, securities sales and trading and asset management. The company operates in two reportable business segments: Dominari Financial and Legacy AIkido. The Dominari Financial reportable business segment represents the Company's broker-dealer business, which is composed of mostly underwriting and transactional service activities. The Legacy AIkido reportable business segment includes Aikido Labs, which manages the investments holdings of the legacy entity. It generates the majority of its revenue from the Dominari Financial segment.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.